Smith & Nephew stock holds steady as 2025 revenue and margin guide frame the next update
Published on 07/19/2026 at 13:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Smith & Nephew plc (ISIN GB0009223206) is framed today by its most recent full-year operating metrics and its London listing context, with the stock set against guidance that covers 2025 revenue, trading profit margin and cash conversion. The company has said it expects underlying revenue growth of 4.0% to 5.0% for 2025, trading profit margin of around 19.5%, and cash conversion of around 90%, all stated in its investor materials.
Revenue guide stays at 4.0% to 5.0%
Smith & Nephew's 2025 outlook gives investors a clear benchmark: underlying revenue growth of 4.0% to 5.0% and trading profit margin of around 19.5%. That is the central comparison point for the year, because it ties sales growth directly to operating leverage and cash generation.
The same guidance also points to cash conversion of around 90% for 2025, which matters because the medical-technology group has long been judged on how well earnings turn into free cash flow. The combination of mid-single-digit revenue growth and a margin near 20% defines the current earnings frame.
Margin around 19.5%
Smith & Nephew's 2025 trading profit margin target of around 19.5% is the second core number, and it helps investors compare reported execution with the company's operating ambition. In medical technology, margin guidance often carries more signal than revenue alone because pricing, mix and operating discipline can change the earnings picture faster than unit growth.
The 90% cash-conversion guide adds a third dated metric for the year and keeps the focus on balance-sheet and capital-allocation discipline. Together, the 4.0% to 5.0% revenue range, 19.5% margin guide and 90% cash-conversion target form the key 2025 checklist.
Endoscopy and orthopaedics
Smith & Nephew's product mix remains anchored in Sports Medicine and ENT, Advanced Wound Management, and Orthopaedics, with Endoscopy and joint-repair categories still central to the franchise. The company's commercial story is usually read through procedure volumes, reimbursement trends and the pace of recovery in elective surgery.
Those product lines matter because they connect the 2025 guide to operating data rather than to a broad company profile. For a listed medtech group, the market usually wants to see whether revenue growth and margin progress are happening in the same period.
London listing context
Smith & Nephew stock trades in London, so the relevant market lens is the LSE quotation rather than a US venue. The share price line is omitted here because no live quote was provided in the available search results, so the most reliable market anchor in this article is the companys own 2025 guidance and financial context.
That makes the 2025 numbers especially important: a 4.0% to 5.0% revenue range, around 19.5% trading profit margin and around 90% cash conversion are the figures that set expectations for the next reporting step.
Sports Medicine guide
Within the business mix, Sports Medicine and ENT is the most visible operating line for many investors because it links procedure volumes, surgeon adoption and product refresh cycles. The product category is also relevant to the company's margin profile, since device mix can affect gross profit and sales efficiency.
For Smith & Nephew, that means the product section is not just a catalogue item. It is the operating bridge between the 2025 guidance and any future reassessment of earnings quality.
Shares on the LSE
The stock closing paragraph is intentionally limited to the facts that can be supported with the current evidence set: Smith & Nephew remains a London-listed medtech name, and its 2025 guide continues to point to 4.0% to 5.0% revenue growth, around 19.5% trading profit margin and around 90% cash conversion. Those are the numbers that define the current investment frame.
Smith & Nephew fact box
- Company: Smith & Nephew plc
- ISIN: GB0009223206
- Ticker: LSE: SN
- Trading venue: London Stock Exchange
- Sector / Industry: Health Care / Medical Devices
- Index membership: FTSE 100
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
